



David Kaul

Kontakt

David Kaul

Publikationen (5)

Kroeze S, Schymalla M, Abbasi-Senger N, Buergy D, Geier M, Szuvecs M, Lohaus F, Henke G, Combs S, Stera S, Adebahr S, Sundahl N, Fritz C, Schaule J, Blanck O, Kahl K, Kaul D, Siva S, Gerum S, Claes A, Guckenberger M. Continued versus Interrupted Targeted Therapy during Metastasis-Directed Stereotactic Radiotherapy: A Retrospective Multi-Center Safety and Efficacy Analysis. *Cancers (Basel)* 2021; 13

Kroeze S, Eckert F, Lohaus F, Sackerer I, Skazikis G, Geier M, Szuvecs M, Glatzer M, Schymalla M, Adebahr S, Verhoeff J, Siva S, Roeder F, Kahl K, Blanck O, Kaul D, Fritz C, Schaule J, Guckenberger M. Metastasis directed stereotactic radiotherapy in NSCLC patients progressing under targeted- or immunotherapy: efficacy and safety reporting from the 'TOaSTT' database. *Radiat Oncol* 2021; 16:4.

Schaule J, Lohaus F, Abbasi-Senger N, Henke G, Szuvecs M, Geier M, Sundahl N, Buergy D, Dummer R, Eckert F, Adebahr S, Schymalla M, Kroeze S, Blanck O, Stera S, Kahl K, Roeder F, Combs S, Kaul D, Claes A, Guckenberger M. Correction to: Predicting survival in melanoma patients treated with concurrent targeted- or immunotherapy and stereotactic radiotherapy : Melanoma brain metastases prognostic score. *Radiat Oncol* 2020; 15:280.

Schaule J, Lohaus F, Abbasi-Senger N, Henke G, Szuvecs M, Geier M, Sundahl N, Buergy D, Dummer R, Eckert F, Adebahr S, Schymalla M, Kroeze S, Blanck O, Stera S, Kahl K, Roeder F, Combs S, Kaul D, Claes A, Guckenberger M. Predicting survival in melanoma patients treated with concurrent targeted- or immunotherapy and stereotactic radiotherapy : Melanoma brain metastases prognostic score. *Radiat Oncol* 2020; 15:135.

Käsmann L, Mäurer M, Panje C, Rosenbrock J, Sautter L, Schmitt D, Süß C, Thieme A, Trommer-Nestler M, Ziegler S, Ebert N, Medenwald D, Ostheimer C, Krug D, Kloock L, Kaul D, Niyazi M, Blanck O, Baues C, Baumann R, Dobiasch S, Eze C, Fleischmann D, Gauer T, Giordano F, Goy Y, Hausmann J, Henkenberens C, Young DEGRO Trial Group. Predictive and prognostic value of tumor volume and its changes during radical radiotherapy of stage III non-small cell lung cancer : A systematic review. *Strahlenther Onkol* 2017; 194:79-90.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch